83% Response Rate: I-Mab's Novel Gastric Cancer Drug Shows Promise in Phase 1

I-Mab (NASDAQ: IMAB) reported Q2 2025 financial results and business updates, highlighting significant progress in its oncology pipeline. The company's lead drug givastomig showed promising Phase 1b results with an 83% objective response rate in combination with immunochemotherapy for first-line gastric cancers.

I-Mab strengthened its financial position through an underwritten offering raising $61.2 million, resulting in a pro-forma cash balance of $226.8 million as of June 30, 2025. This funding is expected to sustain operations through Q4 2028. The company reported reduced R&D expenses of $3.3 million for Q2 2025, down from $5.2 million in Q2 2024, and a net loss of $5.5 million for Q2 2025.

Key upcoming milestones include topline data from givastomig's Phase 1b dose expansion study expected in Q1 2026. The company also acquired Bridge Health, strengthening its intellectual property portfolio for givastomig.

https://www.stocktitan.net/news/IMAB/i-mab-reports-second-quarter-2025-financial-results-and-provides-ypm4szpsgh4d.html